Differences in repair of DNA cross-links between lymphocytes and epithelial tumor cells from colon cancer patients measured in vitro with the comet assay

Clinical Cancer Research

Volumn 15, Issue 17, 2009, Pages 5466-5472

  Herrera, Mercedes ^a   Dominguez, Gemma ^a   Garcia, Jose M ^a   Peña, Cristina ^a   Jimenez, Carmen ^a   Silva, Javier ^a   Garcia, Vanesa ^a   Gomez, Irene ^a   Diaz, Raquel ^a   Martin, Paloma ^a   Bonilla, Felix ^a  

^a HOSPITAL UNIVERSITARIO PUERTA DE HIERRO   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; DNA; FLUOROURACIL; FOLINIC ACID; OXALIPLATIN;

ADJUVANT CHEMOTHERAPY; AGED; ARTICLE; CANCER PATIENT; CELL ACTIVITY; CELL ISOLATION; CELL TYPE; COLON CANCER; COMET ASSAY; CONTROLLED STUDY; DISEASE MARKER; DNA CROSS LINKING; DNA DAMAGE; DNA REPAIR; EPITHELIUM TUMOR; EXCISION REPAIR; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VITRO STUDY; IRRADIATION; KRUSKAL WALLIS TEST; LYMPHOCYTE; MALE; PARAMETER; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; RADIATION DOSE; TUMOR CELL;

AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; COLONIC NEOPLASMS; COMET ASSAY; DNA DAMAGE; DNA REPAIR; EPITHELIAL CELLS; FEMALE; HUMANS; LYMPHOCYTES; MALE; MIDDLE AGED; ORGANOPLATINUM COMPOUNDS; STATISTICS, NONPARAMETRIC;

EID: 69949111785     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-08-3268     Document Type: Article

References (25)

1. Berwick M, Vineis P. Markers of DNA repair and susceptibility to cancer in humans: an epidemiologic review. J Natl Cancer Inst 2000;92:874-897 (Pubitemid 30429188)
2. Vineis P. Individual susceptibility to carcinogens. Oncogene 2004;23:6477-6483
3. Longley DB, Johnston PG. Molecular mechanisms of drug resistance. J Pathol 2005;205:275-292
4. Redmond KM, Wilson TR, Johnston PG, Longley DB. Resistance mechanisms to cancer chemotherapy. Front Biosci 2008;13:5138-5154
5. Collins AR. The comet assay for DNA damage and repair: principles, applications, and limitations. Mol Biotechnol 2004;26:249-261 (Pubitemid 41490465)
6. McKenna DJ, McKeown SR, Kelvey-Martin VJ. Potential use of the comet assay in the clinical management of cancer. Mutagenesis 2008;23:183-190
7. Collins AR, Oscoz AA, Brunborg G, et al. The comet assay: topical issues. Mutagenesis 2008;23:143-151
8. Moller P. The alkaline comet assay: towards validation in biomonitoring of DNA damaging exposures. Basic Clin Pharmacol Toxicol 2006;98:336-345
9. Faust F, Kassie F, Knasmuller S, Boedecker RH, Mann M, Mersch-Sundermann V. The use of the alkaline comet assay with lymphocytes in human biomonitoring studies. Mutat Res 2004;566:209-229 (Pubitemid 38472028)
10. Almeida GM, Duarte TL, Steward WP, Jones GD. Detection of oxaliplatin-induced DNA crosslinks in vitro and in cancer patients using the alkaline comet assay. DNA Repair (Amst) 2006;5:219-225 (Pubitemid 43069522)
11. Blasiak J, Arabski M, Krupa R, et al. Basal, oxidative and alkylative DNA damage, DNA repair efficacy and mutagen sensitivity in breast cancer. Mutat Res 2004;554:139-148 (Pubitemid 39140822)
12. Jianlin L, Jiliang H, Lifen J, Wei Z, Baohong W, Hongping D. Measuring the genetic damage in cancer patients during radiotherapy with three genetic end-points. Mutagenesis 2004;19:457-464 (Pubitemid 39611595)
13. Collins AR,Dusinska M, Horvathova E,Munro E, Savio M, Stetina R. Inter-individual differences in repair of DNA base oxidation, measured in vitro with the comet assay. Mutagenesis 2001;16:297-301. (Pubitemid 32684778)
14. Langie SA, Knaapen AM, Brauers KJ, van BD, van Schooten FJ, Godschalk RW. Development and validation of a modified comet assay to phenotypically assess nucleotide excision repair. Mutagenesis 2006;21:153-158
15. Gaivao I, Piasek A, Brevik A, Shaposhnikov S, Collins AR. Comet assay-based methods for measuring DNA repair in vitro; estimates of inter- and intra-individual variation. Cell Biol Toxicol 2009;25:45-52.
16. Mu D, Wakasugi M, Hsu DS, Sancar A. Characterization of reaction intermediates of human excision repair nuclease. J Biol Chem 1997;272:28971-28979 (Pubitemid 27498182)
17. Evans E, Moggs JG, Hwang JR, Egly JM, Wood RD. Mechanism of open complex and dual incision formation by human nucleotide excision repair factors. EMBO J 1997;16:6559-6573 (Pubitemid 27483280)
18. Hartley JM, Spanswick VJ, Gander M, et al. Measurement of DNA cross-linking in patients on ifosfamide therapy using the single cell gel electrophoresis (comet) assay. Clin Cancer Res 1999;5:507-512 (Pubitemid 29131958)
19. Singh NP, McCoy MT, Tice RR, Schneider EL. A simple technique for quantitation of low levels of DNA damage in individual cells. Exp Cell Res 1988;175:184-191
20. Maindrault-Goebel F, de GA, Louvet C, et al. Evaluation of oxaliplatin dose intensity in bimonthly leucovorin and 48-hour 5-fluorouracil continuous infusion regimens (FOLFOX) in pretreated metastatic colorectal cancer. Oncology Multidisciplinary Research Group (GERCOR). Ann Oncol 2000;11:1477-1483
21. Misset JL, Bleiberg H, Sutherland W, Bekradda M, Cvitkovic E. Oxaliplatin clinical activity: a review. Crit Rev Oncol Hematol 2000;35:75-93.
22. Dip R, Camenisch U, Naegeli H. Mechanisms of DNA damage recognition and strand discrimination in human nucleotide excision repair. DNA Repair (Amst) 2004;3:1409-1423 (Pubitemid 39221739)
23. Koberle B, Masters JR, Hartley JA, Wood RD. Defective repair of cisplatin-induced DNA damage caused by reduced XPA protein in testicular germ cell tumours. Curr Biol 1999;9:273-276 (Pubitemid 29139312)
24. Koberle B, Roginskaya V, Wood RD. XPA protein as a limiting factor for nucleotide excision repair and UV sensitivity in human cells. DNA Repair (Amst) 2006;5:641-648
25. Welsh C, Day R, McGurk C, Masters JR, Wood RD, Koberle B. Reduced levels of XPA, ERCC1 and XPF DNA repair proteins in testis tumor cell lines. Int J Cancer 2004;110:352-361 (Pubitemid 38649885)